Department of Diagnostic Pathology, Kochi University, Nankoku, Kochi783-8505, Japan.
Department of Ophthalmology, Kochi University, Nankoku, Kochi 783-8505, Japan.
Acta Med Okayama. 2020 Aug;74(4):335-343. doi: 10.18926/AMO/60372.
Since the discovery of the NAB2-STAT6 gene fusion in 2013, solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) have been considered the same disease. STAT6 nuclear stain is approved as a highly sensitive and specific marker to diagnose SFT/HPC from other tumors with similar histology. As the next step, detection of fusion variants that may predict clinical malignancy of SFT/HPC has been attempted. However, no fusion variants with a clear relation to malignancy have been identified. In this study, the clinical and histological backgrounds of 23 Japanese patients diagnosed with SFT/HPC from 2000 to 2019 at Kochi University Hospital were examined to identify factors potentially related to recurrence. A significant relationship to recurrence was detected for mitosis ≥ 1/10 HPF (400×), necrosis, and Ki-67>5%. These findings indicate that a deliberate investigation of histological features such as mitosis and necrosis is crucial for the clinical observation of SFT/ HPC patients. In addition, Ki-67 was revealed to be a useful parameter to predict recurrence in SFT/HPC patients.
自 2013 年发现 NAB2-STAT6 基因融合以来，孤立性纤维肿瘤（SFT）和血管外皮细胞瘤（HPC）被认为是同一种疾病。STAT6 核染色被批准为一种高度敏感和特异的标志物，可用于诊断 SFT/HPC，与具有相似组织学的其他肿瘤区分开来。作为下一步，已经尝试检测可能预测 SFT/HPC 临床恶性程度的融合变体。然而，尚未发现与恶性程度有明确关系的融合变体。在这项研究中，检查了 2000 年至 2019 年在高知大学医院诊断为 SFT/HPC 的 23 名日本患者的临床和组织学背景，以确定与复发相关的潜在因素。有丝分裂≥1/10 HPF（400×）、坏死和 Ki-67>5%与复发有显著关系。这些发现表明，仔细研究有丝分裂和坏死等组织学特征对于 SFT/HPC 患者的临床观察至关重要。此外，Ki-67 被证明是预测 SFT/HPC 患者复发的有用参数。
